Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Gianvito Donati"'
Autor:
Federica Negri, Gianluca Tomasello, Rodolfo Passalacqua, Alessandra Curti, Matteo Brighenti, Lucio Olivetti, Mario Martinotti, Wanda Liguigli, Rossana Poli, Gianvito Donati, Silvia Lazzarelli, Massimo Rovatti
Publikováno v:
Gastric Cancer. 17:711-717
We previously studied a dose-dense TCF (TCF-dd) regimen demonstrating its feasibility and an activity comparable to epirubicin-based chemotherapy and TCF q3w in terms of overall survival and time to progression (TTP). We report here the final results
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec8f21ee7ff9ca9117f1ab41cef19f8e
https://doi.org/10.1007/s10120-013-0317-z
https://doi.org/10.1007/s10120-013-0317-z
Autor:
Sebastiano Buti, Gianvito Donati, Silvia Lazzarelli, Gianluca Tomasello, Matteo Dalla Chiesa, Rodolfo Passalacqua, Matteo Brighenti, Rodrigo Kraft Rovere
Publikováno v:
Cancer Chemotherapy and Pharmacology. 67:41-48
To evaluate a new strategy of two sequential, intensified chemotherapy regimens in metastatic gastric cancer.Chemo-naïve patients with metastatic gastric cancer were enrolled to receive 4 cycles of TCF-dd (docetaxel initially 85 mg/m(2) and cisplati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75e09250692c22649ac1ca211744e92e
https://doi.org/10.1007/s00280-010-1281-5
https://doi.org/10.1007/s00280-010-1281-5
Autor:
Matteo Dalla Chiesa, Massimo Buononato, Sebastiano Buti, Gianvito Donati, Matteo Brighenti, Silvia Lazzarelli, Rodrigo Kraft Rovere, Gianluca Tomasello, Antonio Brunelli, Federica Negri, Rodolfo Passalacqua, Mario Martinotti
Publikováno v:
Tumori Journal. 96:48-53
Aims and background Previous studies have reported that in early breast cancer, lymphomas and advanced bladder cancer, dose-dense chemotherapy may be more effective than conventional treatments. In metastatic gastric cancer, chemotherapy with docetax
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7bee165c94d944d91292383f3b3ae41
https://doi.org/10.1177/030089161009600108
https://doi.org/10.1177/030089161009600108
Autor:
Matteo Brighenti, Sebastiano Buti, Massimo Buononato, Antonio Brunelli, Federica Negri, Matteo Dalla Chiesa, Rodolfo Passalacqua, Gianluca Tomasello, Gianvito Donati, Silvia Lazzarelli
Publikováno v:
Tumori. 93(3)
Aims and background Previous phase II studies have reported that combinations of oxaliplatin, folinic acid and 5-fluorouracil or irinotecan, folinic acid and 5-fluorouracil are associated with good efficacy and an acceptable safety profile in metasta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07401d5adf51a2e5b7919506709d4ea6
https://pubmed.ncbi.nlm.nih.gov/17679458
https://pubmed.ncbi.nlm.nih.gov/17679458